Diagnostic Performance of Urinary Keratin 17 Immunocytochemistry (URO17®) During Hematuria Evaluation: A Retrospective Study

Background/Objectives: Urinary biomarkers may assist hematuria risk stratification, but diagnostic performance must be assessed against an appropriate reference standard. We evaluated urinary keratin 17 immunocytochemistry (URO17®) during hematuria evaluation and compared it with urine cytology. Methods: This retrospective, single-center study included adults evaluated between August 2019 and March 2026. The analytic cohort comprised 746 specimens from 612 patients. Formal diagnostic accuracy analyses used one result-independently selected specimen per patient in the reference-standard cohort. URO17® positivity was defined as at least 10 keratin 17-positive cells. Sensitivity and specificity were compared using paired McNemar tests; atypical cytology was classified as negative in the primary comparison. Results: The reference-standard analysis included 313 patients, including 20 with histopathologically confirmed urothelial carcinoma. URO17® sensitivity was 90.0% (95% confidence interval, 69.9–97.2), specificity 90.1% (86.1–93.0), and negative predictive value 99.2% (97.3–99.8). Cytology sensitivity was 20.0% and specificity 98.6%. URO17® was 70.0 percentage points more sensitive and 8.5 percentage points less specific (both p < 0.001). Quantitative cell counts yielded an area under the receiver operating characteristic curve of 0.938. Patients without reference-standard verification were analyzed descriptively. Conclusions: URO17® demonstrated higher sensitivity but lower specificity than conventional cytology when atypical cytology was classified as negative. The high negative predictive value reflects, in part, the 6.4% cancer prevalence in the verified cohort. Selective verification and the small number of cancer-positive patients limit interpretation. Prospective multicenter validation is needed to define its adjunctive clinical role.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-11-18
DOI
https://doi.org/10.3390/diagnostics16223846
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Diagnostic Performance of Urinary Keratin 17 Immunocytochemistry (URO17®) During Hematuria Evaluation: A Retrospective Study

Nam W. Kim, David M. Nudell, Yair Lotan, Mark W. Noller et al.
1 links
Diagnostics
Bladder and Urothelial Cancer Treatments
article

Diagnostic Performance of Urinary Keratin 17 Immunocytochemistry (URO17®) During Hematuria Evaluation: A Retrospective Study

Nam W. Kim, David M. Nudell, Yair Lotan, Mark W. Noller, Sholeh Jahanfard, Sasha Homayoun, David Noller, Chelgis Jahanfard, Anamika Bisen, Shahram Shawn Gholami
article en

Abstract

Background/Objectives: Urinary biomarkers may assist hematuria risk stratification, but diagnostic performance must be assessed against an appropriate reference standard. We evaluated urinary keratin 17 immunocytochemistry (URO17®) during hematuria evaluation and compared it with urine cytology. Methods: This retrospective, single-center study included adults evaluated between August 2019 and March 2026. The analytic cohort comprised 746 specimens from 612 patients. Formal diagnostic accuracy analyses used one result-independently selected specimen per patient in the reference-standard cohort. URO17® positivity was defined as at least 10 keratin 17-positive cells. Sensitivity and specificity were compared using paired McNemar tests; atypical cytology was classified as negative in the primary comparison. Results: The reference-standard analysis included 313 patients, including 20 with histopathologically confirmed urothelial carcinoma. URO17® sensitivity was 90.0% (95% confidence interval, 69.9–97.2), specificity 90.1% (86.1–93.0), and negative predictive value 99.2% (97.3–99.8). Cytology sensitivity was 20.0% and specificity 98.6%. URO17® was 70.0 percentage points more sensitive and 8.5 percentage points less specific (both p < 0.001). Quantitative cell counts yielded an area under the receiver operating characteristic curve of 0.938. Patients without reference-standard verification were analyzed descriptively. Conclusions: URO17® demonstrated higher sensitivity but lower specificity than conventional cytology when atypical cytology was classified as negative. The high negative predictive value reflects, in part, the 6.4% cancer prevalence in the verified cohort. Selective verification and the small number of cancer-positive patients limit interpretation. Prospective multicenter validation is needed to define its adjunctive clinical role.

DiagnosticsVol. 16(22)
Silicon Valley University (US), The University of Texas Southwestern Medical Center (US)
Good health and well-being
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon